Merck, Sanofi are latest companies to add medications to TrumpRx

Merck added three Type 2 diabetes drugs to TrumpRx, cutting Januvia, Janumet and Janumet XR to $84.57 from $330, a 74% discount. Sanofi is joining as the 13th company on the government prescription-discount website, with Toujeo priced at $35 from $428.57, a 92% markdown, alongside other diabetes, tuberculosis and blood medications. The move is tied to the Trump administration’s most-favored-nation pricing effort and comes as 100% tariffs on imported branded and patented pharmaceuticals are being used as leverage.

Analysis

This is less a one-off headline and more an accelerating distribution event for U.S. drug pricing. The near-term beneficiaries are the companies making the concessions because they buy tariff relief and political optionality, but the bigger market signal is that Medicare/consumer pricing pressure is becoming more coordinated across the sector. That should compress dispersion in branded pharma valuation multiples: investors will increasingly pay less for perceived pricing power unless a name has a protected launch cadence or a pipeline strong enough to offset forced discounts.

The second-order effect is that the market may underappreciate how selective this pressure is. Mature primary-care franchises with high U.S. exposure and durable volume can absorb lower realized pricing better than specialty-heavy peers, while companies with a heavier reliance on ex-U.S. or ex-U.S.-manufactured supply could see a double hit if tariff waivers are used as leverage. Over months, this likely shifts negotiating power toward payers and PBMs, but over days the stock reaction should remain muted because the revenue impact is small relative to total company scale.

For MRK, the issue is not the direct dollar hit; it is the precedent that the market now has a visible reference point for what political concessions can look like. If management repeatedly opts into these programs, it could support tariff relief but also cap sentiment around future price/mix expansion in diabetes and adjacent primary-care categories. For SNY, the bigger risk is that investors start extrapolating broader price discipline into insulin and established hospital products, which could make the stock look cheaper on forward multiples without actually improving long-term growth quality.

The contrarian read is that this may be slightly bullish for the best-positioned incumbents: they are effectively buying down regulatory overhang at a controllable cost, and that can reduce tail-risk discounting into the next election cycle. The trade-off is that once concessions become the default path, the sector loses some optionality on future pricing actions, so the upside is in relative value rather than outright beta.

Key Decisions for Investors

• Long MRK vs. XBI for 1-3 months: MRK has more balance-sheet and earnings resilience to absorb pricing concessions, while the broader biotech basket is more exposed to multiple compression from policy overhang.
• Long SNY on weakness into the next 2-4 weeks with a tight stop: the incremental pricing concession is manageable versus the company’s broader portfolio, and the stock can rerate if investors conclude the hit is mostly symbolic rather than structural.
• Short basket of U.S.-heavy mature pharma names against a long basket of globally diversified names for 3-6 months: fade companies with high Medicare/consumer exposure and limited near-term launch catalysts.
• Buy medium-dated put spreads on a basket proxy like IBB or XPH if additional TrumpRx additions continue: the risk/reward improves if the policy broadens from isolated concessions to a repeated negotiation framework.
• Avoid adding to high-multiple pharma ahead of further tariff headlines for the next 30-60 days: the primary risk is not earnings erosion but repeated narrative compression that keeps forward P/Es pinned.